Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy : A global, observational study
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases..
BACKGROUND: Since the introduction of the combination treatment of anti-programmed death-ligand 1 antibody atezolizumab and anti-VEGF antibody bevacizumab (AB), median overall survival in HCC has drastically improved. However, evidence on the efficacy and safety of the novel treatment standard in patients with prior exposure to systemic treatment is scarce. The aim of this global, multicenter, observational study was to evaluate the efficacy and safety of AB in patients after previous systemic therapy.
METHODS: We screened our global, multicenter, prospectively maintained registry database for patients who received any systemic therapy before AB. The primary end point was overall survival; secondary end points were time-to-progression, progression-free survival, objective response rate, and safety (rate and severity of adverse events).
RESULTS: Among 493 patients who received AB for unresectable HCC, 61 patients received prior systemic therapy and were included in this analysis. The median age of the study population was 66 years, with 91.8% males. Predominant risk factors for HCC were viral hepatitis (59%) and alcohol (23%). Overall survival for AB was 16.2 (95% CI, 14.5-17.9) months, time-to-progression and progression-free survival were 4.1 (95% CI, 1.5-6.6) and 3.1 (95% CI, 1.1-5.1) months, respectively. The objective response rate was 38.2% (7.3% with complete and 30.9% with partial response). Overall survival was not influenced by treatment line (2nd vs. >2nd) or previous systemic treatment modality (tyrosine kinase inhibitors vs. immune checkpoint inhibitors). Treatment-related adverse events of all grades according to Common Terminology Criteria for Adverse Events were documented in 42.6% of patients, with only 13.1% of grade ≥3, including one death.
CONCLUSION: In this observational study, AB emerges as a safe and efficacious treatment option in patients with HCC previously treated with other systemic therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Hepatology communications - 7(2023), 11 vom: 01. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Joerg, Vincent [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.10.2023 Date Revised 12.02.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1097/HC9.0000000000000302 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363815848 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363815848 | ||
| 003 | DE-627 | ||
| 005 | 20240213232538.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/HC9.0000000000000302 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1290.xml |
| 035 | |a (DE-627)NLM363815848 | ||
| 035 | |a (NLM)37889520 | ||
| 035 | |a (PII)e0302 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Joerg, Vincent |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy |b A global, observational study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.10.2023 | ||
| 500 | |a Date Revised 12.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases. | ||
| 520 | |a BACKGROUND: Since the introduction of the combination treatment of anti-programmed death-ligand 1 antibody atezolizumab and anti-VEGF antibody bevacizumab (AB), median overall survival in HCC has drastically improved. However, evidence on the efficacy and safety of the novel treatment standard in patients with prior exposure to systemic treatment is scarce. The aim of this global, multicenter, observational study was to evaluate the efficacy and safety of AB in patients after previous systemic therapy | ||
| 520 | |a METHODS: We screened our global, multicenter, prospectively maintained registry database for patients who received any systemic therapy before AB. The primary end point was overall survival; secondary end points were time-to-progression, progression-free survival, objective response rate, and safety (rate and severity of adverse events) | ||
| 520 | |a RESULTS: Among 493 patients who received AB for unresectable HCC, 61 patients received prior systemic therapy and were included in this analysis. The median age of the study population was 66 years, with 91.8% males. Predominant risk factors for HCC were viral hepatitis (59%) and alcohol (23%). Overall survival for AB was 16.2 (95% CI, 14.5-17.9) months, time-to-progression and progression-free survival were 4.1 (95% CI, 1.5-6.6) and 3.1 (95% CI, 1.1-5.1) months, respectively. The objective response rate was 38.2% (7.3% with complete and 30.9% with partial response). Overall survival was not influenced by treatment line (2nd vs. >2nd) or previous systemic treatment modality (tyrosine kinase inhibitors vs. immune checkpoint inhibitors). Treatment-related adverse events of all grades according to Common Terminology Criteria for Adverse Events were documented in 42.6% of patients, with only 13.1% of grade ≥3, including one death | ||
| 520 | |a CONCLUSION: In this observational study, AB emerges as a safe and efficacious treatment option in patients with HCC previously treated with other systemic therapy | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a atezolizumab |2 NLM | |
| 650 | 7 | |a 52CMI0WC3Y |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Scheiner, Bernhard |e verfasserin |4 aut | |
| 700 | 1 | |a D Alessio, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Fulgenzi, Claudia A M |e verfasserin |4 aut | |
| 700 | 1 | |a Schönlein, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Kocheise, Lorenz |e verfasserin |4 aut | |
| 700 | 1 | |a Lohse, Ansgar W |e verfasserin |4 aut | |
| 700 | 1 | |a Huber, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Wege, Henning |e verfasserin |4 aut | |
| 700 | 1 | |a Kaseb, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yinghong |e verfasserin |4 aut | |
| 700 | 1 | |a Mathew, Antony |e verfasserin |4 aut | |
| 700 | 1 | |a Kuang, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Muzaffar, Mahvish |e verfasserin |4 aut | |
| 700 | 1 | |a Abugabal, Yehia I |e verfasserin |4 aut | |
| 700 | 1 | |a Chamseddine, Shadi |e verfasserin |4 aut | |
| 700 | 1 | |a Phen, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Cheon, Jaekyung |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Pei-Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Balcar, Lorenz |e verfasserin |4 aut | |
| 700 | 1 | |a Krall, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a Ang, Celina |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Saeed, Anwaar |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yi-Hsiang |e verfasserin |4 aut | |
| 700 | 1 | |a Bengsch, Bertram |e verfasserin |4 aut | |
| 700 | 1 | |a Rimassa, Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Weinmann, Arndt |e verfasserin |4 aut | |
| 700 | 1 | |a Stauber, Rudolf |e verfasserin |4 aut | |
| 700 | 1 | |a Korolewicz, James |e verfasserin |4 aut | |
| 700 | 1 | |a Pinter, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Singal, Amit G |e verfasserin |4 aut | |
| 700 | 1 | |a Chon, Hong Jae |e verfasserin |4 aut | |
| 700 | 1 | |a Pinato, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Schulze, Kornelius |e verfasserin |4 aut | |
| 700 | 1 | |a von Felden, Johann |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology communications |d 2017 |g 7(2023), 11 vom: 01. Nov. |w (DE-627)NLM273051806 |x 2471-254X |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:11 |g day:01 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/HC9.0000000000000302 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 11 |b 01 |c 11 | ||